Zocor vs. Vytorin

See how Zocor and Vytorin compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Zocor is a single-ingredient statin that lowers LDL cholesterol, while Vytorin combines that same statin with ezetimibe to block cholesterol absorption for extra LDL reduction.

  • Vytorin's added ezetimibe component can lower LDL more than simvastatin alone, but it costs substantially more without insurance coverage.

  • Both drugs contain simvastatin, so they share warnings about muscle-related side effects and interactions with strong CYP3A4 inhibitors.

Zocor vs. Vytorin Drug Summary

Zocor

Zocor (simvastatin) is a statin that lowers LDL cholesterol by blocking an enzyme the liver uses to make cholesterol. It is taken as a single tablet once daily, in doses from 10 mg to 80 mg. It has been prescribed since 1991 and is now widely available as a low-cost generic.

Vytorin

Vytorin combines simvastatin, the same statin found in Zocor, with ezetimibe, a drug that blocks cholesterol absorption in the intestine. It is taken as one tablet once daily, in combined doses from 10 mg/10 mg to 10 mg/80 mg. The two-drug combination is designed to lower LDL more than a statin can on its own.

Zocor vs. Vytorin Side Effects

Zocor

Most common
Upper respiratory infection (up to 9%)
Headache (up to 7%)
Abdominal pain (up to 7%)
Constipation (up to 7%)

Vytorin

Most common
Headache (up to 5.8%)
Increased ALT (up to 3.7%)
Upper respiratory tract infection (up to 3.6%)
Myalgia (up to 3.6%)

Zocor vs. Vytorin Dosage

Zocor

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg once daily At the start
Maximum dose 80 mg once daily If needed
Dose changes 3 increases As tolerated

Vytorin

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg/10 mg once daily At the start
Maximum dose 10 mg/80 mg once daily If needed
Dose changes 3 increases As tolerated

Zocor vs. Vytorin Indications

Zocor

Zocor is FDA-approved to lower LDL cholesterol in adults with primary hyperlipidemia and to treat familial forms of high cholesterol. It also reduces the risk of heart attack, stroke, and death in adults with heart disease or diabetes at high cardiovascular risk. It is not approved for children under age 10.

  • Lowers LDL cholesterol in primary hyperlipidemia

  • Treats heterozygous familial hypercholesterolemia (ages 10+)

  • Adjunct therapy for homozygous familial hypercholesterolemia

  • Reduces cardiovascular event risk in high-risk adults

Vytorin

Vytorin is FDA-approved to lower LDL cholesterol, total cholesterol, triglycerides, and Apo B, and to raise HDL cholesterol in adults with primary hyperlipidemia. It is also approved for homozygous familial hypercholesterolemia and homozygous sitosterolemia. It is not approved for patients with active liver disease.

  • Lowers LDL, total cholesterol, and triglycerides

  • Raises HDL cholesterol

  • Treats homozygous familial hypercholesterolemia

  • Treats homozygous sitosterolemia

Zocor vs. Vytorin Pros and Cons

Zocor

Zocor has been used since 1991, giving it decades of long-term safety and outcome data across large populations. It is available as an inexpensive generic, which keeps it accessible for most insurance plans and cash-paying patients. Its main limitation is that, as a statin alone, it may not lower LDL enough for some patients who need additional treatment.

Pros

  • Decades of long-term real-world safety data

  • Available as a low-cost generic, roughly $75 to $100 a month without insurance

  • Simple single-ingredient statin with well-known interactions

  • Four dose strengths allow gradual titration

Cons

  • LDL lowering may plateau at higher doses without add-on therapy

  • Higher myopathy risk at the 80 mg dose, which is restricted

  • Single mechanism only targets liver cholesterol production

  • May need a second drug added for very high LDL levels

Vytorin

Vytorin combines simvastatin with ezetimibe to block cholesterol from two directions: production in the liver and absorption in the gut. The IMPROVE-IT trial showed this combination reduced major cardiovascular events compared to simvastatin alone in patients after a heart attack. Its main tradeoff is a much higher price than simvastatin alone.

Pros

  • Dual mechanism lowers LDL more than a statin alone

  • IMPROVE-IT trial showed reduced cardiovascular events post-ACS

  • Combines two cholesterol pathways in a single daily pill

  • Also approved for homozygous sitosterolemia

Cons

  • Costs roughly $600 to $650 a month without insurance, before savings programs

  • Contraindicated in active liver disease

  • Higher risk of elevated liver enzymes than simvastatin alone

  • Patients not at goal on 40 mg switch statins rather than titrate up

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.